STANDING ORDER TO DISPENSE NALOXONE

Authority: This standing order is issued in accordance with RCW 69.41.095(5), which allows for “[t]he secretary or the secretary’s designee [to] issue a standing order prescribing opioid overdose reversal medications to any person at risk of experiencing an opioid-related overdose or any person or entity in a position to assist a person at risk of experiencing an opioid-related overdose.” The physician issuing this standing order has been designated to do so by the Secretary of Health.

Purpose: The purpose of this standing order is to aid persons experiencing an opioid related overdose by facilitating distribution of the opioid antagonist naloxone to people in Washington.

Authorization: This standing order shall be considered a naloxone prescription for an eligible person or entity. This standing order authorizes a pharmacist to dispense naloxone to any eligible person or entity. This standing order authorizes any eligible person or entity in the State of Washington, including but not limited to any wholesaler licensed in the State of Washington, to possess, store, deliver, distribute, or administer naloxone.

An eligible person or entity is any person at risk of experiencing an opioid-related overdose or any person or entity in a position to assist a person at risk of experiencing an opioid-related overdose. These could include a natural person, such as an individual at risk of an opioid-related overdose or a family member, friend or acquaintance of that individual; or a legal person, such as an ambulance service, police department, or school or other educational institution that could be in a position to assist a person at risk of experiencing an opioid-related overdose.

Terms and Conditions: Any pharmacist dispensing naloxone to eligible persons or entities, as defined above, must provide written instructions on the proper response to an opioid-related overdose, including instructions for seeking immediate medical attention.

Pharmacists using this standing order to dispense naloxone should list the provider who signed this order as the prescriber.

Any individual or entity that dispenses, distributes, or delivers an opioid overdose reversal medication as authorized by this section shall ensure that directions for use are provided. Pharmacies and other entities are strongly encouraged to provide in-person training and allow hands-on practice with a demonstration kit and/or show a training video to persons receiving naloxone for the first time. Training may include information on the proper response to an opioid-related overdose; instructions on the role of naloxone; recognizing a potential opioid-related overdose; verifying unresponsiveness; calling 911; administering naloxone; starting rescue breathing; administering a second dose of naloxone if needed; and providing post-overdose care.

Written printable instructions and a training video for lay persons on responding to an opioid-related overdose and administering naloxone are available at: https://www.doh.wa.gov/YouandYourFamily/DrugUserHealth/OverdoseandNaloxone/NaloxoneInstructions

To request this document in another format, call 1-800-525-0127. Deaf or hard of hearing customers, please call 711 (Washington Relay) or email civil.rights@doh.wa.gov.
Naloxone HCL Dispensing Procedures

Pharmacies and other entities can dispense and deliver the following naloxone products to eligible persons and entities based on availability and preference. Eligible persons and entities include persons at risk of experiencing an opioid-related overdose or persons or entities in a position to aid persons experiencing an opioid-related overdose.

Intramuscular Naloxone Hydrochloride Injection Solution (0.4 mg/ml)

Dispense: Two or more 1ml single dose vials of naloxone HCL (0.4mg/1ml) inj. and sufficient quantity of 3 ml syringes with 23 or 25 gauge 1.5” needles for the number of doses dispensed.

Directions for use: Call 911. Inject the entire solution of the vial intramuscularly in the shoulder or thigh. Repeat after two to three minutes as needed if no or minimal response.

Refills: As needed.

NARCAN Nasal Spray (4mg/0.1 ml)

Dispense: Two or more NARCAN® 4mg nasal sprays.

Directions for use: Call 911. Administer a single spray of NARCAN® in one nostril. Repeat after two to three minutes as needed if no or minimal response.

Refills: As needed.

Generic Naloxone Hydrochloride Nasal Spray (4mg/0.1ml)

Dispense: Two or more generic naloxone HCl 4mg nasal sprays.

Directions for use: Call 911. Administer a single spray in one nostril. Repeat after two to three minutes as needed if no or minimal response.

Refills: As needed.

Evzio® Naloxone HCl Injection, USP auto-injector (2mg)

Dispense: Two or more Evzio® 2mg auto-injector devices and 1 trainer device.

Directions for use: Remove auto-injector device from outer case. Remove red safety cover on bottom of device. Place black end of device firmly against person's thigh. Press firmly and listen as device counts down from 3 to 1. Once the device gives approval, remove device from thigh. Repeat after two to three minutes as needed if no or minimal response.

Refills: As needed.
Expiration, Renewal and Review
This standing order will automatically expire on 02/01/2023 or on the date that the physician who signed the order revokes it or ceases to act as the Secretary of Health's designee, whichever comes sooner. This standing order shall be reviewed on a regular basis against current best practices and may be revised or updated if new information about naloxone administration necessitates it.